RUBIN PAUL D 4
4 · BioAge Labs, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
BioAge (BIOA) CMO Paul Rubin Exercises Options, Sells 7,433 Shares
What Happened
Paul D. Rubin, Chief Medical Officer of BioAge Labs (BIOA), exercised stock option(s) on Feb 2, 2026 to acquire a total of 7,433 shares (5,433 at $4.11 and 2,000 at $6.57), paying $35,470 in exercise costs. The same day he sold all 7,433 shares in an open‑market transaction at $18.75 per share for proceeds of $139,369. (The Form 4 also lists the derivative items converted/ disposed at $0.00, reflecting the option-to-stock conversion.)
Key Details
- Transaction date: 2026-02-02 (Form 4 filed 2026-02-03; appears timely).
- Exercises: 5,433 shares @ $4.11 = $22,330; 2,000 shares @ $6.57 = $13,140; total exercise cost $35,470.
- Sale: 7,433 shares @ $18.75 = $139,369 (open-market sale).
- Net cash before taxes/fees (sale proceeds minus exercise cost): ~$103,899.
- Shares owned after transaction: not specified in the provided filing excerpt.
- Notable footnotes: transaction executed under a Rule 10b5-1 trading plan adopted Nov 5, 2024 (F1); the options were fully vested per award terms (vested as of May 11, 2024, with a monthly 1/48th vesting schedule beginning April 1, 2022) (F2, F3).
- Transaction codes: M = option exercise/conversion; S = sale.
Context
This was effectively a cashless exercise and immediate sale: Rubin exercised vested options and then sold the acquired shares the same day. Sales following option exercises are common and, when done under a 10b5‑1 plan, are pre‑scheduled trades rather than ad‑hoc market timing. The filing does not, in itself, indicate management sentiment about BioAge’s outlook.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-02$4.11/sh+5,433$22,330→ 5,433 total - Exercise/Conversion
Common Stock
[F1]2026-02-02$6.57/sh+2,000$13,140→ 7,433 total - Sale
Common Stock
[F1]2026-02-02$18.75/sh−7,433$139,369→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F2]2026-02-02−5,433→ 10,870 totalExercise: $4.11Exp: 2030-06-30→ Common Stock (5,433 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F3]2026-02-02−2,000→ 5,383 totalExercise: $6.57Exp: 2032-05-28→ Common Stock (2,000 underlying)
Footnotes (3)
- [F1]The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
- [F2]This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
- [F3]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.